Abstract
The role and use of independent data monitoring committees (IDMCs) has evolved over the past decades. The Food and Drug Administration and European Medicines Agency have issued guidelines on the role and functioning of such committees. In general, data monitoring committees are recommended for large, often randomised clinical trials involving life-threatening diseases, studies performed in vulnerable populations or where the experimental intervention can potentially harm the trial participant. Such committees play an important role in trials evaluating treatments with the potential to prolong life or reduce the risk of major adverse health outcomes.Typically, oncology clinical trials fall within these recommendations, as they are often large, randomised, multicentric protocols aiming at improving survival outcomes by exploring the use of study treatments that may be associated with a significant risk of serious, even life-threatening adverse events. IDMCs are required for National Cancer Institute phase III randomised trials, European Organisation for Research and Treatment of Cancer phase II/III trials with formal interim analyses, early-stopping rules or adaptive studies. The primary role of an IDMC of ensuring the safety of study participants and maintaining clinical trial integrity is particularly important in oncology trials, due to the nature of the disease, the potential for treatment toxicity and for instilling confidence that the clinical trial data are reliable. A clear understanding by IDMC members of the natural course of the disease, treatment landscape, importance and relevance of certain adverse events in trial participants, clinical trial methodology in general and stopping rules for oncology trials in particular, is crucial for the functioning of an IDMC.It is recommended that IDMC members should be experienced trialists, have a track record of strong clinical, statistical and/or methodological expertise and the required level of independence, as they play a highly important role in the protection of study participants, and in commercially and strategically important go/no decisions. Ideally, IDMC members should have relevant experience or have some training, mentorship or guidelines.
Reference32 articles.
1. Independent data monitoring committees: an update and overview;Sartor;Urol Oncol,2015
2. National Institutes of Health (NIH) guide. volume 8 number 8, 1979. Available: file:///C:/Users/Admin/Documents/My%20documents/From%20PC%203%20Sept%202018/2020%20-%202019%20Schoffski%20-%20data%20monitoring%20article/From%20internet%20-%20marked%20up/NIH%20guide.%20Volume%208%20number%208,%20June%205,%201979.pdf [Accessed 27 Feb 2020].
3. U.S. Department of Health and Human Services. Food and Drug Administration . Guidance for clinical trial sponsors. Establishment and operation of clinical trial data monitoring committees. March 2006. omb control No. 0910-0581 (expiration date: 10/31/2021). Available: https://www.fda.gov/media/75398/download [Accessed 27 Feb 2020].
4. CTSA Collaborative DSMB Workgroup . DSMB training manual. Medford, MA: Tufts Digital Library, 2018. https://www.tuftsctsi.org/research-services/regulatory/data-and-safety-monitoring-board-training-manual-for-investigator-initiated-studies/
5. Data monitoring committees: promoting best practices to address emerging challenges;Fleming;Clin Trials,2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献